STOCK TITAN
  1. Home
  2. News
  3. LGND

Ligand Pharmaceuticals, Inc. - LGND STOCK NEWS

Welcome to our dedicated news page for Ligand Pharmaceuticals (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ligand Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ligand Pharmaceuticals's position in the market.

News
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) will report its first quarter 2024 financial results on May 7, 2024, after the close of the U.S. financial markets. A conference call will be held at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences earnings
-
News
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) partners with the University of Minnesota and CURx Pharmaceuticals to present new data on Captisol-enabled™ Topiramate Injection as a potential substitute for oral topiramate in treating neurological conditions like epilepsy. The IV formulation of topiramate simplifies replacement therapy, allowing for proper dosing in various clinical scenarios. Ligand holds the license for IV topiramate and is entitled to milestone payments and royalties on global sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
News
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Rhea-AI Summary
Ligand Pharmaceuticals announces the launch of Pelthos Therapeutics and the appointment of Scott Plesha as CEO. Pelthos aims to commercialize ZELSUVMI, a topical gel for molluscum contagiosum, expected to be available in late 2024. The product received FDA approval and is developed using Pelthos' proprietary technology platform. Ligand acquired the rights to ZELSUVMI from Novan, Inc. in 2023. Scott Plesha brings over 30 years of pharmaceutical industry experience to the role, with a successful track record in building commercial organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
News
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) CEO and CFO to participate in a fireside chat at the Barclays Healthcare Conference. The event is on March 14, 2024, in Miami.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
conferences
-
News
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) granted a non-qualified stock option award to an employee for 15,100 shares of common stock under the Inducement Plan. The options have an exercise price of $78.70 per share, a ten-year term, and will vest over four years. This award aims to attract and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
-
News
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
Rhea-AI Summary
Ligand Pharmaceuticals' partner Eisai receives approval for Fycompa injection formulation in Japan, utilizing Ligand's Captisol technology. Fycompa is a novel antiepileptic drug, enhancing treatment options for patients with epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
News
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated appoints Richard Baxter as Senior Vice President of Investment Operations and Karen Reeves, M.D., as Senior Vice President of Clinical Strategy and Investments. The company aims to enhance deal capabilities and capitalize on industry developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
management
-
News
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) will announce full year and fourth quarter 2023 financial results on February 27, 2024. A conference call will be held to discuss financial results and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
conferences earnings
-
News
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) granted non-qualified stock option awards to two non-executive employees, totaling 93,700 shares, 32,750 restricted stock units, and 40,000 performance stock units. The options have an exercise price of $74.17 per share and will vest over four years. RSUs will vest over three years, and PSUs will vest based on company performance objectives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
News
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) announced FDA approval of ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum in adults and pediatric patients. ZELSUVMI is the first novel drug for this treatment and the first and only topical prescription medication that can be applied by patients, parents, or caregivers at home. It is expected to be commercially available in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
Stock LGND logo
Ligand Pharmaceuticals, Inc.

Nasdaq:LGND

LGND Rankings

#2255 Ranked by Market Cap
#2636 Ranked by Stock Gains
N/A Ranked by Dividends

LGND Stock Data

1.44B
16.67M
5.93%
94.12%
3.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About LGND

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.